Labcorp raises annual profit forecast on strong testing demand By Reuters
Labcorp raised its 2026 adjusted earnings forecast to $18.10 to $18.55 per share from $17.70 to $18.35 and lifted its annual revenue outlook to $14.71 billion to $14.83 billion. It reported Q2 revenue of $3.73 billion and adjusted EPS of $4.99, both above estimates, supported by diagnostic demand and growth in drug-development services.
How this was made
The 30-second read
Why it matters
Raised guidance and segment outperformance are likely to drive estimate revisions and re-rate expectations, but the noted premarket drop suggests investors may be reacting to segment organic growth concerns or prior expectations.
Market read
A concrete guidance raise with segment beats provides a fresh catalyst for earnings-model updates, even as the stock initially trades lower premarket.
What to watch
Segment-level growth mix matters: Diagnostics segment revenue was slightly below expectations, so the market may be discounting quality of growth even with higher consolidated guidance.
Background
Reuters reports Labcorp’s Q2 beat and an upward revision to 2026 adjusted EPS and revenue guidance, citing steady diagnostic testing demand and growth in drug-development services.
Ticker impact
Labcorp raised its 2026 adjusted EPS forecast to $18.10-$18.55 and lifted revenue guidance after better-than-expected Q2 results.
Likely positive bias for the stock versus prior guidance, though the article notes shares fell about 6% premarket, implying positioning risk.
The text provides specific raised forecast ranges and segment revenue beats, which are direct inputs to valuation and forward estimates.
Market effects
Signals resilience in diagnostic testing demand and biopharma lab services spending, potentially improving sentiment for managed lab and CRO-adjacent peers.
Primarily US healthcare services sentiment; limited direct regional spillover beyond US-listed diagnostics.
Moderate, as diagnostic demand and pharma R&D spend are global drivers but the disclosure is company-specific.
Counterpoint
The Diagnostics Laboratories organic growth concern (investors focused on softer-than-expected organic growth vs Quest) could cap upside despite raised full-year numbers.
Key entities
- companyLabcorp
Diagnostics and biopharma laboratory services provider that raised 2026 adjusted EPS and revenue guidance after better-than-expected Q2 results.
- companyQuest Diagnostics
Peer referenced for comparison after it raised its own full-year profit forecast following routine testing demand.
- analyst_firmLeerink Partners
Cited for commentary on what investors were likely focused on regarding Labcorp’s organic growth.
